TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00002618

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cytarabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cytarabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mercaptopurine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mercaptopurine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: low-LET cobalt-60 gamma ray therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: low-LET cobalt-60 gamma ray therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: low-LET electron therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: low-LET electron therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: low-LET photon therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: low-LET photon therapy
Study: NCT02165098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine prolonged release tablet A
Description: Cariprazine prolonged release tablet A - fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine prolonged release tablet B
Description: Cariprazine prolonged release tablet B - fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine capsule
Description: Cariprazine capsule - fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine PR tablet A
Description: Cariprazine Prolonged Release tablet A - fed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine PR tablet B
Description: Cariprazine Prolonged Release tablet B - fed
Study: NCT02442804

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: POMx
Description: Pomegranate supplement (1g) by mouth twice per day for 7 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (for POMx, containing no antioxidant contents; 1g) capsule by mouth twice per day for 7 days
Study: NCT01319552

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fresh transfusion
Description: 1 unit autologous transfusion of red blood cells stored for 3-7 days under standard conditions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fresh transfusion
Description: 1 unit autologous transfusion of red blood cells stored for 3-7 days under standard conditions

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Old transfusion
Description: 1 unit autologous transfusion of red blood cells stored for 40-42 days under standard conditions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Old transfusion
Description: 1 unit autologous transfusion of red blood cells stored for 40-42 days under standard conditions
Study: NCT03200886

Intervention type: DEVICE
Intervention: Sinovial H-L
Description: Patients were treated with an hybrid form of hyaluronic acid (Sinovial H-L) obtained through thermo-chemical processes from the combination of high (1100-1400 kDa) and low (80-100 kDa) MW fractions.

Intervention type: DRUG
Intervention: Triamcinolone Acetonide
Description: The patients have received two i.a. injections (at baseline and 15 days apart) of 0.5 ml of triamcinolone acetonide (Kenacort® 20 mg, Bristol-Myers Squibb Srl)
Study: NCT00892216

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupressure (BioBand)
Description: Band will remain on from 20 minutes before surgery until the end of the hospital stay.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Acupressure (BioBand)
Description: Band will remain on from 20 minutes before surgery until the end of the hospital stay. The same band will be placed and turned so the beads face the corresponding point on the dorsal surface of the upper limb area.
Study: NCT00900952

Intervention type: OTHER
Intervention: Clinical record review
Study: NCT02543060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: stannous fluoride toothpaste
Description: 0.454% stannous fluoride toothpaste

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: cavity protection toothpaste
Description: 0.243% sodium fluoride toothpaste
Study: NCT01122121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprorelin SR
Description: Leuprorelin SR injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprorelin SR
Description: Leuprorelin SR injection

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy 70 +/- 4 Gy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutamide
Description: Flutamide tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flutamide
Description: Flutamide tablets
Study: NCT01890252

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyper CL
Description: The Hyper CL is hyper osmotic contact lens that absorb fluids from the cornea and by that reduces corneal edema.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyper CL
Description: The Hyper CL is hyper osmotic contact lens that absorb fluids from the cornea and by that reduces corneal edema.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saline solution
Description: saline solution of 5% NaCl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline solution
Description: saline solution of 5% NaCl
Study: NCT02879201

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Slow efficiency dialysis
Description: Slow dialysis 4 times weekly 8 hours CVVHDF predilution mode
Study: NCT00442364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polidocanol (1%) Microfoam (Varisolve)
Description: Varisolve polidocanol 1% microfoam, maximum of 20ml injected into affected great saphenous vein.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovenous Microfoam Occlusion
Description: Varisolve® polidocanol microfoam injection under duplex guidance to fill proximal and distal great saphenous vein and varicose tributaries.
Study: NCT01675167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: Buprenorphine HCl Buccal Film at doses ranging from 150-900 mcg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo Buccal Film twice daily
Study: NCT02527421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFD01 Spray
Description: DFD-01 (betamethasone dipropionate) Spray, 0.05%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFD01 Spray
Description: DFD-01 (betamethasone dipropionate) Spray, 0.05%
Study: NCT01192685

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: TMS will be administered to subjects 5 days a week-typically Monday through Friday, for 6 weeks.

Intervention type: DEVICE
Group type: OTHER
Intervention: near infrared spectroscopy (NIRS)
Description: near infrared spectroscopy (NIRS) will be used to measure the blood flow in the brain
Study: NCT03435783

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Electronic Intervention
Description: The brief electronic intervention will allow users to receive normative feedback based on their alcohol use and sexual activity. Users who show interest in changing their behavior will also be asked to create a plan to do so.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention-Matched Control
Description: Participants will view a video clip on general health promotion that is a similar length as the intervention arm.
Study: NCT00853567

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proellex
Description: 25 mg oral daily dose vs. 50 mg oral daily dose vs. placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proellex
Description: 25 mg oral daily dose vs. 50 mg oral daily dose vs. placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo
Study: NCT04215497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PSSE
Description: Physiotherapeutic Scoliosis-Specific Exercises (PSSE) group will receive exercise for 30-40 mins in a day, twice in a week, totally 8 weeks and 16 hours.~Control group will be taught the basic elements of corrective exercises and want them to do the practising during 8 weeks at home.
Study: NCT02452515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1142524
Description: 5 mg BAY1142524 or placebo given as 5 mg IR tablet twice daily for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1142524
Description: 10 mg BAY1142524 or placebo given as 2 x 5 mg IR tablets twice daily as for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1142524
Description: 25 mg BAY1142524 or placebo given as 5 x 5 mg IR tablets twice daily for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1142524
Description: 50 mg BAY1142524 or placebo given 1 x 50 mg IR tablet once daily for 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The patients will be treated orally with combinations of IR tablets containing placebo to achieve the indicated dosages.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The patients will be treated orally with combinations of IR tablets containing placebo to achieve the indicated dosages.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The patients will be treated orally with combinations of IR tablets containing placebo to achieve the indicated dosages.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The patients will be treated orally with combinations of IR tablets containing placebo to achieve the indicated dosages.
Study: NCT05828056

Intervention type: DEVICE
Intervention: Wearable activity tracker
Description: Garmin smartwatch will record features, such as activities, heart rate, sleep, through smartphone App
Study: NCT01955629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept AVE0005
Description: Pharmaceutical form: Concentrate for solution for infusion; Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Pharmaceutical form: Concentrate for solution for infusion; Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Pharmaceutical form: Tablets; Route of administration: Oral
Study: NCT02758483

Intervention type: OTHER
Group type: OTHER
Intervention: Control diet
Description: Diet with a little quantity of sugars (30.40g; 12.7% of total carbohydrates of the diet).

Intervention type: OTHER
Group type: OTHER
Intervention: Test Diet
Description: Diet with foods containing moderate quantity of sucrose in composition (80.22g; 30.2% of total carbohydrates of the diet).
Study: NCT02259088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab (RFB002)
Description: Ranibizumab 0.5 mg/0.05 mL for intravitreal injection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser
Description: Laser photocoagulation according to Early Treatment Diabetic Retinopathy Study (ETDRS) guidelines

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sham injection
Description: Imitation of an intravitreal injection consisting of an empty vial and an injection syringe without a needle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham laser
Description: Imitation of an active laser
Study: NCT03100552

Intervention type: DIAGNOSTIC_TEST
Intervention: Endoscopic imaging
Description: Analysis of the presence of dysplasia within sessile serrated polyps (SSP) using endoscopic imaging (high definition white light +- narrow band imaging)
Study: NCT01441362

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 90 degrees rotation
Description: Double-lumen tube intubation with 90 degrees rotation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 180 degrees rotation
Description: Double-lumen tube intubation with 180 degrees rotation
Study: NCT00220636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Aripiprazole dose ranging from 5 to 30 mg/day, augmenting antidepressant treatment. Aripiprazole is used as an augmenting medication on an open label basis for patients on antidepressant medication who continue to have depressive symptoms. This is an open label case series in which all subjects receive aripiprazole augmentation. There is no comparator group.
Study: NCT02709382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefepime and Tazobactam combination
Study: NCT05532306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin 400 mg film coated tablet (1*400mg)
Description: an immediate release film-coated tablet containing 400 mg Ribavirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Copegus® 200 mg film coated tablet (2*200mg)
Description: an immediate release film-coated tablet containing 200 mg Ribavirin
Study: NCT04321707

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 15O-H2O PET/MR
Description: All included patients will have a 15O-H2O PET/MR scan performed at baseline and a scan performed after NAC, prior to cystectomy.
Study: NCT00677989

Intervention type: PROCEDURE
Intervention: Laparoscopic appendectomy
Description: laparoscopic appendectomy:did appendectomy by laparoscopic manipulation

Intervention type: PROCEDURE
Intervention: Open appendectomy
Description: open appendectomy: did appendectomy by laparotomy
Study: NCT03208985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Use Phase (Ulipristal Acetate, 30 mg)
Description: All subjects enrolled in the use phase of this open-label study will be given the opportunity to purchase and take 30 mg of ulipristal acetate.~Subjects are to use the investigational product based on their understanding of the directions on the outer packaging including Drug Facts Label and inside the product packaging (in the Consumer Information Leaflet).
Study: NCT00310661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarizotan
Description: The dose of sariztan HCI for each patient in the drug arm will be given 2mg b.i.d. orally during the first 4 weeks of treatment. If efficacy is inadequate and there are no safety concerns, the option to raise the dose to 5mg b.i.d is given. After 8 weeks of treatment, the option to raise the dose to 7mg bid is given. Dose may remain the same or may be decreased again to the previous dose.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for each patient randomized to the placebo arm will be given placebo (oral, twice daily) in a pill form for 12 weeks
Study: NCT03760861

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype Microcapsule Treatment
Description: The subject will be sedated and using an endoscope, a prototype microcapsule will be placed into the gastric corpus. Then, an external handheld magnet will be applied to inflate the balloon encapsulated in the microcapsule. Upon ascertaining the full inflation based on the endoscopic visualization, the investigator will wait another 10 minutes after that to observe how the subject feels before manually puncturing the balloon with needle knife, and retrieving the punctured balloon with the RothNet through the mouth.
Study: NCT02940314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP1503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP1503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1103
Study: NCT06328413

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: photobiomodulation
Description: Photobiomodulation application at different extraoral and intraoral points for 60 seconds with a wavelength of 940 nm in repeated sessions after the extraction of third molar

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Leukocyte and Platelet Rich Fibrin
Description: Leukocyte and platelet rich fibrin ( blood product centrifuged for 12 minutes at 2700rpm) application after third molar extraction, single session.
Study: NCT01497366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400 mg (2 × 200 mg tablets) administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG
Description: Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RBV
Description: Ribavirin (RBV) administered as 200 mg tablets up to 1200 mg in a divided daily dose~* Dose of sofosbuvir+RBV group based on baseline weight: \< 75kg = 1000 mg and ≥ 75 kg = 1200 mg~* Dose of PEG+RBV group: 800 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) administered as 200 mg tablets up to 1200 mg in a divided daily dose~* Dose of sofosbuvir+RBV group based on baseline weight: \< 75kg = 1000 mg and ≥ 75 kg = 1200 mg~* Dose of PEG+RBV group: 800 mg
Study: NCT04207619

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hyperinsulinemic-hypoglycemic clamp
Description: An intravenous catheter will be placed in an antecubital vein for infusion of insulin and glucose. A second catheter will be placed retrograde in a dorsal vein of the contra-lateral hand for blood withdrawal. The hand will be placed in a heating box or pad at 70°C for arterialization of venous blood. A primed infusion of regular insulin (120 mU/min/m2) will be initiated and continued for approximately 2 hours. Beginning 20 minutes prior to the start of the insulin infusion, arterialized venous blood glucose will be measured at 5 minute intervals via a Hemocue or YSI analyzer. Following initiation of insulin infusion, blood glucose will be allowed to fall to 50 mg/dL and then maintained at this level using a variable infusion of exogenous dextrose (20% solution). Our goal is to achieve steady-state (blood glucose stabilized at 50 +/- 5 mg/dL) within the first 45 minutes following the start of insulin infusion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 13C-MRS procedure/Acetate infusion
Description: Glial metabolism will be measured via MRS utilizing a simultaneous intravenous infusion of 13C labeled acetate. An intravenous catheter will be placed in a vein of each arm, one to infuse 13C-acetate and the other to draw blood samples
Study: NCT03904992

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive web app
Description: Access to a progressive web app for the promotion of healthy habits in preescholers through the participant's smatphone
Study: NCT02184624

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELLIPTA
Description: Dry powder inhaler (placebo) with two blister strips. One placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELLIPTA
Description: Dry powder inhaler (placebo) with two blister strips. One placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELLIPTA
Description: Dry powder inhaler (placebo) with two blister strips. One placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELLIPTA
Description: Dry powder inhaler (placebo) with two blister strips. One placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELLIPTA
Description: Dry powder inhaler (placebo) with two blister strips. One placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DISKUS/ACCUHALER
Description: Placebo inhaler with one blister strip containing lactose monohydrate.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MDI
Description: Placebo inhaler containing propellant (1,1,1, 2-Tetrafluoroethane).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TURBUHALER
Description: Placebo inhaler containing lactose monohydrate.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HANDIHALER
Description: Placebo inhaler containing lactose monohydrate in a capsule.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BREEZEHALER
Description: Placebo inhaler containing lactose monohydrate in a capsule.
Study: NCT01996761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: porcine brain peptide (Cerebrolysin)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00946153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: In the Dose-Escalation Component of the study, lenvatinib will be administered as continuous once-daily oral dosing. Dose-escalation will occur based on safety information obtained during Cycle 1. The recommended dose for the Expansion Component of the study will use the MTD in Cycle 1.
Study: NCT02587273

Intervention type: DRUG
Group type: OTHER
Intervention: Fentanyl
Description: In this study there will be no administration of an investigational product per study protocol. The dosage of fentanyl will be according to the ICU's established procedures and the treating physician's judgment. The specific dose of fentanyl given to each patient will differ extensively. By routine, the ICU's in our hospital usually dose the fentanyl infusion as 0,5 - 6 μg/kg/hrs (kg = Ideal Body Weight). The intervention in this study will be a per protocol cessation in administration of fentanyl over a 6 hours period. Arterial blood samples, urine samples, pre and post filter samples and samples from dialysate will be collected during this 6 hours. If the patient needs opioid analgesia during the period, alternative opioid analgesia will be given.